spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Pre-Filled Syringes & Injectable Drug Devices Europe

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

16-17 January 2019
Copthorne Tara Hotel, London

SMi is proud to present their 11th annual European conference and exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019, in London. 

The conference will offer a deep insight into key areas within the field, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. Our line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles.

Join us in January 2019 to network, benchmark and learn about developments at the forefront of the Pre-Filled Syringes and Injectable Drug Devices industry.

Chairs for 2019:

· James Mellman, Device Manager, Novartis

· Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured Speakers:

· Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

· Cedric Gysel, Staff Device Engineer, Janssen

· Davide Mercadante, Sr Associate Quality Drug Devices, Biogen

· Elise Legendre, Head of Late stage PFS Development, Sanofi

· James Mellman, Device Manager, Novartis

· Joan Malmstrom, Principal Scientist, Novo Nordisk

· Justin Wright, Global Head of Innovation, Novartis

· Maggie Reiff, Associate Device Engineer, Pfizer

· Mathieu Rigollet, Senior PFS Engineer, Roche

· Michael Becker, Design Engineer, Boehringer Ingelheim

· Reinhard Scheller, Commercial ManagerCyclo Olefin Polymers - COP Europe, Zeon Europe GmbH

· Shota Arakawa, Researcher, Mitsubishi Gas Chemical Company

· Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS

· Steve Chamberlain, Device Engineering Manager, GSK

· Suraj Ramachandran, Director, Merck

· Vikas Jaitely, Senior Manager Pharmaceutical Sciences & CMC Regulatory Intelligence,Merck



Key Highlights this January:

  • Engage and interact with like-minded individuals through 5+ hours of dedicated networking time, within the conference programme
  • Gain insight from fellow field experts through our interactive programme structure and our fantastic delegation with representation from all aspects of the industry, as well as cross-industry thought leaders and decision makers
  • Discover new technologies being developed to circumvent common industry hurdles and discuss ways in which to overcome the barriers of implementation
  • Hear case studies about the streamlining of injectable device development – from development to market
  • Interact with regulatory bodies in order to glean insight into the most recent revisions to regulation and the best ways to integrate them into business practices
  • Learn about current drug development programmes which will have an imminent impact on the PFS and Injectable devices sector and discuss the influence which drug development has on device development
  • Discuss patient centricity and the impact of human factors on design processes

View the full agenda online: www.pre-filled-syringes.com/samwl

phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web https://bit.ly/2QROsgw
email Copthorne Tara Hotel, London
 
Print this page
Send to a friend
   
spacer
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>


News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement